Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
This randomized, double-blinded, placebo-controlled trial tested the hypothesis that 20mg of melatonin before and during the first cycle of adjuvant chemotherapy for breast cancer (ACBC) reduced the side effects associated with cognitive impairment. We evaluated the effects of melatonin on cognition, depressive symptoms and sleep quality, and whether these effects were related to serum levels of Brain Derived Neurotrophic Factor (BDNF) and its receptor, tropomyosin kinase B (TrkB). Thirty-six women were randomly assigned to receive melatonin or placebo for 10 days. To evaluate cognitive performance, we used the Trail-Making-Test Parts A and B (A-B), Rey Auditory-Verbal Learning Test (RAVLT), Controlled Oral Word Association Test (COWAT) and an inhibitory task type Go / No-Go. Our results revealed that melatonin improved executive function on TMT scores, enhanced episodic memory (immediate and delayed) and recognition on RAVLT, and increased verbal fluency in the orthographic COWAT. The TMT-A-B(A-B) were negatively correlated with baseline levels of TrkB and BDNF, respectively. At the end of treatment, changes in TrkB and BDNF were inversely associated with depressive symptoms and sleep quality, but not with the TMT scores. These results suggest a neuroprotective effect of melatonin to counteract the adverse effects of ACBC on cognitive function, sleep quality and depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Psychometric properties of the Beck Depression Inventory-II: a comprehensive review
Wang, Y.-P., & Gorenstein, C. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2012-1048 · Cited by 1,577
Right hemispheric dominance of inhibitory control: An event-related functional MRI study
Garavan, H., Ross, T. J., & Stein, E. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8301 · Cited by 1,394
Turner, L., Shamseer, L., Altman, D. G., Weeks, L., Peters, J., Kober, T., Dias, S., Schulz, K. F., Plint, A. C., & Moher, D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000030.pub2 · Cited by 740 · cited 1×
“This trial was structured according to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guideline and was carried out in accordance with the Declaration of Helsinki[23].”
MethodGlobal Connectivity of Prefrontal Cortex Predicts Cognitive Control and Intelligence
Cole, M. W., Yarkoni, T., Repovs, G., Anticevic, A., & Braver, T. S. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0536-12.2012 · Cited by 613 · cited 1×
“Although studies generally indicate that large-scale brain networks including prefrontal and parietal structures mediate the trail making test performance, according to Cole and colleagues[46], higher scores on measures of cognitive control (i.”
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538 · cited 1×
“This neurotrophic factor is essential to long-term potentiation, learning and memory[11], and serves as a critical regulator of synaptic plasticity, neuronal survival and neurogenesis[12].”
BackgroundSchwertner, A., Conceição dos Santos, C. C., Costa, G. D., Deitos, A., de Souza, A., de Souza, I. C. C., Torres, I. L. S., da Cunha Filho, J. S. L., & Caumo, W. (2013) · Pain · doi:10.1016/j.pain.2013.02.025 · Cited by 155
Self-citationChen, W. Y., Giobbie-Hurder, A., Gantman, K., Savoie, J., Scheib, R., Parker, L. M., & Schernhammer, E. S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2944-4 · Cited by 130
The effect of melatonin on sleep and quality of life in patients with advanced breast cancer
Innominato, P. F., Lim, A. S., Palesh, O., Clemons, M., Trudeau, M., Eisen, A., Wang, C., Kiss, A., Pritchard, K. I., & Bjarnason, G. A. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-015-2883-6 · Cited by 111 · cited 2×
“The improvement on sleep quantity produced by melatonin in our study is consistent with previous results found in patients with metastatic breast cancer[21].”
BackgroundResultLund Rasmussen, C., Klee Olsen, M., Thit Johnsen, A., Aagaard Petersen, M., Lindholm, H., Andersen, L., Villadsen, B., Groenvold, M., & Pedersen, L. (2015) · Cancer · doi:10.1002/cncr.29563 · Cited by 52
Cited by
Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline
Grassi, L., Zachariae, R., Caruso, R., Palagini, L., Campos-Ródenas, R., Riba, M. B., Lloyd-Williams, M., Kissane, D., Rodin, G., McFarland, D., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102047 · Cited by 96
Nissen, E. R., Neumann, H., Knutzen, S. M., Henriksen, E. N., Amidi, A., Johansen, C., von Heymann, A., Christiansen, P., & Zachariae, R. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae041 · Cited by 46
Oldacres, L., Hegarty, J., O'Regan, P., Murphy‐Coakley, N. M., & Saab, M. M. (2023) · Psycho-Oncology · doi:10.1002/pon.6073 · Cited by 36
Sun, Q., Fan, J., Zhao, L., Qu, Z., Dong, Y., Wu, Y., & Gu, S. (2025) · doi:10.20944/preprints202502.1825.v1 · Cited by 10
Metadata
- Authors
- Palmer, A. C. S., Zortea, M., Souza, A., Santos, V., Biazús, J. V., Torres, I. L. S., Fregni, F., & Caumo, W.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-04-17
- Volume
- 15
- Issue
- 4
- Pages
- e0231379
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W3017038206
- Cited by
- 114
- References
- 10
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.